JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

JNJ

238.68

-0.55%↓

UNH

274.9

-0.55%↓

TMO

546.83

+0.89%↑

ABT

111.08

+0.23%↑

ISRG

492.83

+1.14%↑

Search

Denali Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

20.83 -1.09

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

20.06

Max

21.1

Schlüsselkennzahlen

By Trading Economics

Einkommen

-2.8M

-127M

Angestellte

517

EBITDA

-12M

-134M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+55.5% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

25. Feb. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.3B

3.6B

Vorheriger Eröffnungskurs

21.92

Vorheriger Schlusskurs

20.83

Nachrichtenstimmung

By Acuity

25%

75%

44 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Denali Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Feb. 2026, 17:25 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Buy Biotech Orna Therapeutics for Up to $2.4 Billion -- Update

9. Feb. 2026, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Domestic Policy Measures -- Market Talk

9. Feb. 2026, 23:43 UTC

Market Talk

Gold Falls on Possible Technical Correction -- Market Talk

9. Feb. 2026, 23:14 UTC

Market Talk

WiseTech's Bull Reckons AI-Driven Selloff Is Overdone -- Market Talk

9. Feb. 2026, 22:29 UTC

Market Talk

Australian Coking Coal Price Seen Falling Once Supply Disruptions Ease -- Market Talk

9. Feb. 2026, 22:19 UTC

Market Talk

Pro Medicus's Business Case Made More Compelling by AI Adoption -- Market Talk

9. Feb. 2026, 22:08 UTC

Market Talk

Minerals 260 Bull Bets on Production Scale, Takeover Appeal -- Market Talk

9. Feb. 2026, 22:01 UTC

Ergebnisse

Friedman Industries Sees 4Q Sales Volume to Generally Consistent With 3Q, With Sequential Improvement in Sales Margins

9. Feb. 2026, 21:59 UTC

Ergebnisse

Friedman Industries: Hedging Activities Continued to Perform as Anticipated by Mitigating Impact of Commodity Price Volatility

9. Feb. 2026, 21:59 UTC

Ergebnisse

Friedman Industries: Average Selling Prices Began to Improve as Quarter Progressed

9. Feb. 2026, 21:58 UTC

Ergebnisse

Friedman Industries 3Q Sales $168M >FRD

9. Feb. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

9. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Feb. 2026, 21:48 UTC

Ergebnisse

Friedman Industries 3Q EPS 43c >FRD

9. Feb. 2026, 21:17 UTC

Ergebnisse

Kyndryl Stock Drops 55%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

9. Feb. 2026, 21:13 UTC

Market Talk

U.S. Ethanol Crush Margins Near Break-Even -- Market Talk

9. Feb. 2026, 21:04 UTC

Ergebnisse

Retail Sales Data Should Confirm a Robust Holiday Season -- Barrons.com

9. Feb. 2026, 20:30 UTC

Market Talk

Oil Futures Gain As U.S.-Iran Risk Premium Holds -- Market Talk

9. Feb. 2026, 20:02 UTC

Market Talk

U.S. Natural Gas Falls on Warmer Weather Outlook -- Market Talk

9. Feb. 2026, 19:42 UTC

Market Talk

Japan's Yield Curve Expected to Flatten -- Market Talk

9. Feb. 2026, 19:31 UTC

Market Talk

Nike Seen Regaining Relevance With Consumers -- Market Talk

9. Feb. 2026, 19:27 UTC

Market Talk

Gold Climbs Back Over $5,000/oz -- Market Talk

9. Feb. 2026, 19:05 UTC

Market Talk

Nike Returns to List of Hottest Brands -- Market Talk

9. Feb. 2026, 18:19 UTC

Market Talk

Lower Dollar Doesn't Translate to Boost in Grains -- Market Talk

9. Feb. 2026, 17:41 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, AppLovin, Monday.com, Valaris, and More -- Barrons.com

9. Feb. 2026, 17:31 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Are Today's Movers: Kyndryl, Hims & Hers, Novo Nordisk, Monday.com, Valaris, Cleveland-Cliffs, and More -- Barrons.com

9. Feb. 2026, 17:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Financial Services Roundup: Market Talk

9. Feb. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. Feb. 2026, 17:17 UTC

Market Talk

Century Aluminum Announces Next Steps of Okla. Project -- Market Talk

9. Feb. 2026, 17:16 UTC

Ergebnisse

Kyndryl Stock Drops 56%. It's So Much Worse Than an Earnings Miss. -- Barrons.com

Peer-Vergleich

Kursveränderung

Denali Therapeutics Inc Prognose

Kursziel

By TipRanks

55.5% Vorteil

12-Monats-Prognose

Durchschnitt 32.78 USD  55.5%

Hoch 40 USD

Tief 25 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Denali Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

10

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

13.355 / 16.44Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

44 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat